New imaging agent could sharpen cancer treatment decisions
NCT ID NCT07168785
First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This early-phase study will test a new radioactive tracer called [18F]-AraG in just 5 people with advanced head and neck cancer. Participants will receive two PET/CT scans (before and during standard chemoradiotherapy) to see if the tracer's uptake matches immune cell activity and predicts treatment response. The goal is to improve risk assessment, not to treat the cancer directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [18F]-AraG radiotracer (a radioactive dye for PET scans)
- What this could lead to
- If successful, this could lead to a more accurate way to predict how well head and neck cancer responds to chemoradiotherapy, helping doctors tailor treatment.
- What could go wrong
- This is a very early, tiny study (only 5 people) testing a new imaging agent. It is not designed to prove the tracer improves outcomes, only to see if it correlates with immune activity and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could skipping some neck radiation spare patients side effects?
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can an immunotherapy combo shrink head and neck tumors before surgery?
- Vaccine trains immune system to fight HPV-Positive head and neck tumors
- New scan could sharpen detection of head and neck cancers
- New combo therapy targets tough head and neck cancers